AbCellera Biologics Inc. (ABCL) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Vancouver, BC, 加拿大. 现任CEO为 Carl Hansen.
ABCL 拥有 IPO日期为 2020-12-11, 596 名全职员工, 在 NASDAQ Global Select, 市值为 $1.14B.
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
